Citadel Advisors
CARM

Citadel Advisors’s Carisma Therapeutics CARM Stock Holding History

Citadel Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,855
Closed -$22.6K – 14764
2022
Q4 		$22.6K Sell
1,855
-680
-27% -$7.14K ﹤0.01% 13043
2022
Q3 		$22K Buy
2,535
+60
+2% +$817 ﹤0.01% 12031
2022
Q2 		$40K Sell
2,475
-1,305
-35% -$14.9K ﹤0.01% 12061
2022
Q1 		$46K Sell
3,780
-8,155
-68% -$114K ﹤0.01% 12841
2021
Q4 		$195K Sell
11,935
-12,480
-51% -$251K ﹤0.01% 11883
2021
Q3 		$387K Buy
24,415
+3,405
+16% +$163K ﹤0.01% 10489
2021
Q2 		$1.94M Buy
21,010
+6,770
+48% +$432K ﹤0.01% 6697
2021
Q1 		$740K Buy
14,240
+12,080
+559% +$570K ﹤0.01% 8825
2020
Q4 		$58K Buy
2,160
+1,065
+97% +$27K ﹤0.01% 10508
2020
Q3 		$31K Buy
+1,095
New +$21.9K ﹤0.01% 9748
2020
Q1 		– Sell
-825
Closed -$17K – 9619
2019
Q4 		$17K Sell
825
-565
-41% -$13K ﹤0.01% 8959
2019
Q3 		$33K Buy
1,390
+685
+97% +$16K ﹤0.01% 8821
2019
Q2 		$21K Buy
+705
New +$21.1K ﹤0.01% 8936
2019
Q1 		– Sell
-995
Closed -$28K – 9289
2018
Q4 		$28K Sell
995
-565
-36% -$18K ﹤0.01% 8637
2018
Q3 		$67K Sell
1,560
-2,315
-60% -$90.2K ﹤0.01% 8726
2018
Q2 		$151K Buy
+3,875
New +$171K ﹤0.01% 8064

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's CARM Position: Q2 2024 in Review

Citadel Advisors sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 38,973 shares — an estimated $88.5K sold.

Citadel Advisors first reported a position in CARM in Q3 2016 and held it in 23 quarters. The position peaked at $802K in Q1 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Citadel Advisors reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 38,973 Carisma Therapeutics shares in Q2 2024, an estimated $88.5K.
  • Citadel Advisors first reported a position in Carisma Therapeutics in Q3 2016 and held it in 23 quarters.
  • Citadel Advisors's Carisma Therapeutics position peaked at $802K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.